1. HOME

Biosimilars

Project Name INN Indications Clinical Info
Project NameCT-P44
INNDaratumumab
Indicationsmultiple myeloma
Clinical InfoClinical Phase 3
Project NameCT-P51
INNPembrolizumab
Indications Melanoma, lung cancer
Clinical InfoPhase 3
Project NameCT-P53
INNOcrelizumab
IndicationsMultiple sclerosis
Clinical InfoPhase 3
Project NameCT-P55
INNSecukinumab
IndicationsPsoriasis
Clinical InfoPhase 3

It is not intended for product promotion or sales. For more information, contact your doctor or healthcare professional.